Livagen is a synthetic peptide bioregulator made of four amino acids: Lysine, Glutamic acid, Aspartic acid, and Alanine (Lys-Glu-Asp-Ala). It was developed based on peptide complexes from liver tissue and is classified as a hepatic bioregulator. In lab studies it showed tissue-specific stimulation of liver explant growth.[4] It is a research compound only and is not approved for human medical use.

How does Livagen work?

Livagen appears to work by loosening overly condensed chromosomal regions in aging cells — a process called deheterochromatinization. As cells age, chromosomes pack tighter, silencing genes. Research found that Livagen can reactivate silenced ribosomal genes and release repressed chromatin regions in elderly lymphocytes,[1] potentially restoring more youthful patterns of gene expression.[6]

What is Livagen used for in research?

Researchers are studying Livagen for age-related changes in gene expression, genomic instability in conditions like atherosclerosis,[2] liver tissue function,[4] and digestive enzyme regulation in aging.[5] All published work is preclinical — meaning cell cultures or animal models — and no human clinical trial data are currently available from the cited sources.

How is Livagen dosed?

Published research does not establish a single standardized dose for Livagen across all study models, so specific amounts vary by protocol. The dosage chart on this page provides a structured reference for researchers, and the on-page calculator can help determine volumes once a concentration is set. Always consult the primary literature and your institution's guidelines before designing experiments.

How do you reconstitute Livagen?

Livagen powder is typically dissolved in bacteriostatic water or sterile water. Add solvent slowly, swirl gently — don't shake. Store the reconstituted solution at 2–8°C for short-term use or freeze at –20°C for longer storage. Protect from light and label clearly with date and concentration. Discard any solution that appears cloudy or discolored.

The published studies cited here are limited to cell culture and animal research, so no human safety profile has been established from these sources. One rat study noted that Livagen is highly resistant to digestion by gut enzymes,[5] which is notable but does not constitute a safety assessment. Livagen is a research compound only — this page does not provide medical advice and the compound should not be used in humans outside of approved research settings.

Livagen Dosage Chart, Protocol & Calculator

A liver peptide bioregulator studied for hepatic function.

Goal	Dose	Frequency	Duration	Evidence	Source
Cited dosing data is being compiled for this compound.

What is Livagen?

Livagen is a short synthetic peptide made of just four amino acids: Lysine–Glutamic acid–Aspartic acid–Alanine (Lys-Glu-Asp-Ala). It belongs to a family of compounds called peptide bioregulators — tiny protein fragments originally derived from specific tissues that appear to "speak" to cells in a tissue-specific way. Livagen was developed based on peptide complexes originally isolated from liver tissue, which is why researchers classify it as a hepatic bioregulator. It is strictly a research compound, not approved for human medical use.

In organotypic culture experiments — basically growing tiny pieces of tissue in a dish — Livagen preferentially stimulated the growth of liver tissue explants compared with explants from other organs. That tissue-specific behavior is one of the hallmarks of this class of peptides.^[4]

How Livagen Works

Think of your chromosomes like a tightly wound garden hose. As cells age, that hose gets coiled up even tighter, and some sections get locked away where nothing can reach them. Those locked sections are called heterochromatin, and the genes buried inside them go quiet — even genes the cell still needs.

Research suggests Livagen may act like a gentle unwinding mechanism. In laboratory studies on lymphocytes (white blood cells) taken from elderly people, Livagen promoted a process called deheterochromatinization — essentially loosening up those overly condensed chromosome regions so that silenced genes can become active again.^[1] It also appears to activate ribosomal genes — the genes responsible for building the protein-making machinery of the cell — and to release genes that had been repressed due to age-related chromatin condensation.^[6]

Importantly, Livagen also appears to be remarkably resistant to digestion. Research in rats found that the peptide hydrolase enzymes of the small intestine barely break it down at all, which means it can potentially survive the gut environment — an unusual property for a peptide.^[5]

What the Research Shows

Here is a plain-English summary of the key studies published so far:

Chromatin activation in aging cells: In one study, blood cells from elderly donors were exposed to Livagen in the lab. The peptide triggered activation of ribosomal genes, loosened tightly packed heterochromatin, and helped release genes that had been silenced by age-related chromosome condensation.^[1]
Confirming the chromatin effect with multiple peptides: A broader study compared five short peptides — including Livagen — on lymphocytes from people aged 75–88. All five activated chromatin, but Livagen was among those that specifically caused decondensation in the pericentromeric regions of chromosomes 1 and 9, regions often heavily locked down in old age.^[6]
Effects in aging lymphocytes confirmed independently: A 2007 study published in the Annals of the New York Academy of Sciences looked at lymphocytes from people aged 80–91. Researchers confirmed that age-related chromosomal condensation progressively silences active genes, and that Livagen could induce deheterochromatinization — reactivating those silenced regions.^[3]
Genomic instability and atherosclerosis: A 2014 study examined patients over 80 with atherosclerosis (plaque build-up in arteries) who showed high levels of genomic instability — damaged, unstable chromosomes. When researchers applied Livagen to cultured cells from these patients, it appeared to normalize several abnormal genomic indicators. The authors suggested this points toward a potential protective role in preventing atherosclerosis-related chromosomal damage.^[2]
Digestive enzyme activity: In a rat study, two weeks of oral Livagen administration reduced digestive enzyme activity in young animals, while in old animals it increased that same enzyme activity — in many cases bringing it back to levels typical of younger animals. This age-dependent, normalizing effect on gut enzyme function was notable.^[5]
Tissue-specific growth stimulation: When tested across multiple tissue types in culture dishes, Livagen specifically stimulated liver tissue growth — matching its origin as a liver-derived peptide complex — while other peptides stimulated their own respective tissues.^[4]

What Livagen Is Being Studied For

Based on the published literature, researchers are exploring Livagen in the following contexts:

Age-related changes in gene expression and chromatin structure^[1]
Genomic instability associated with aging and disease^[2]
Potential protective effects against atherosclerosis-related chromosome damage^[2]
Liver and hepatic tissue function^[4]
Digestive enzyme regulation, especially age-related changes in enzyme activity^[5]

All of this work is preclinical or in vitro (cell and animal studies). No clinical trials in humans have been published in the sources available here. Livagen is a research compound only.

How Livagen Is Dosed in Research

Because published dosing protocols for Livagen are limited and vary depending on the study model being used, there are no universally established research doses at this time — which is why this page does not list specific amounts. Instead, refer to the dosage chart on this page for a structured reference, and use the calculator to work out volumes based on your reconstitution concentration. Always follow your institution's research protocols and consult primary literature before designing any experiment involving this compound.

Mixing and Storing Livagen

Livagen typically arrives as a lyophilized (freeze-dried) white powder. To reconstitute it for research use, bacteriostatic water or sterile water for injection is commonly used — add the solvent slowly to the vial and swirl gently rather than shaking, which can degrade the peptide. Once mixed, store the solution in the refrigerator (2–8°C) and use within a few weeks, or freeze at –20°C for longer-term storage. Protect all peptide solutions from light. Always label vials with the date of reconstitution, concentration, and compound name. Never use a solution that looks cloudy or discolored.

Sources

Effects of Livagen peptide on chromatin activation in lymphocytes from old people. — Bulletin of experimental biology and medicine, 2002. PMID 12533768.
[Genomic instability in atherosclerosis]. — Georgian medical news, 2014. PMID 25541832.
Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals. — Annals of the New York Academy of Sciences, 2007. PMID 17460203.
Tissue-specific effects of peptides. — Bulletin of experimental biology and medicine, 2001. PMID 11713572.
[Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages]. — Advances in gerontology = Uspekhi gerontologii, 2005. PMID 16075683.
Effects of short peptides on lymphocyte chromatin in senile subjects. — Bulletin of experimental biology and medicine, 2004. PMID 15085253.

Livagen Guide & Dosage Chart